

## Supporting Information

# Crossreceptor Interactions between Dopamine D<sub>2L</sub> and Neurotensin NTS<sub>1</sub> Receptors Modulate Binding Affinities of Dopaminergics

Susanne Koschatzky, Nuska Tschammer, Peter Gmeiner\*





Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich-Alexander University,  
Schuhstr. 19, 91052 Erlangen, Germany

**Figure 1.** Emission spectra of the fluorescence detected co-immunoprecipitation of D<sub>2L</sub>-NTS1 heteromer.

Immunoprecipitation with mouse anti-D<sub>2L</sub>-antibody resulted in different intensities of the CFP emission spectra of the investigated probes. The negative controls of lysis buffer (A, black curve), the NTS1-CFP complex (B, green curve) and the co-expression of D<sub>2L</sub> with NTS1 and cytosolic CFP (C, purple curve), exhibited no fluorescence due to the absence of a fluorophore or the lack of precipitation by the antibody or the combination of both circumstances.

The co-expression of D<sub>2L</sub>-CFP and NTS1 (D, blue curve) transiently expressed in HEK293 cells displayed after IP with the anti-D<sub>2</sub>-antibody the most intense CFP-emission spectra.


Figure 1.



**Figure 2..**

Western blot was performed with the mouse anti-D<sub>2</sub>-antibody of the whole cell lysates of HEK293 cells transiently expressing dopamine D<sub>2L</sub> or NTS<sub>1</sub> receptor in comparison to mock transfected cells. D<sub>2L</sub> expressing lysate revealed a strong band at 100 kDa of the D<sub>2L</sub> receptor dimer and a weak band for the glycosylated D<sub>2L</sub> monomer. Mock transfected and NTS<sub>1</sub> expressing cells demonstrated a weak band at 100 kDa of the endogenously expressed D<sub>2</sub> receptor in HEK293 cells (Atwood B. K, Lopez J., Wager-Miller J., Mackie K., Straiker A. (2011) Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. *BMC Genomics* 12, 1-14.).

Labeling of endogenously expressed dopamine D<sub>2L</sub> receptor in HEK 293 cells by western blotting was accounted of low relevance for the fluorescence-detected co-immunoprecipitation due to the missing fluorophore at the endogenous D<sub>2L</sub>.



**Table 1.** Influence of neurotensin on [<sup>3</sup>H]spiperone binding at the D<sub>2L</sub>-NTS<sub>1</sub>-heteromer compared with singly expressed D<sub>2L</sub> receptor membranes and the mixture of mono-expressed D<sub>2L</sub> and NTS<sub>1</sub>.<sup>a</sup>


	Co- expression of D <sub>2L</sub> and NTS <sub>1</sub>		D <sub>2L</sub>		Mixture of singly expressed NTS <sub>1</sub> and D <sub>2L</sub>	
	K <sub>D</sub> [nM]	B <sub>max</sub> [fmol/mg]	K <sub>D</sub> [nM]	B <sub>max</sub> [fmol/mg]	K <sub>D</sub> [nM]	B <sub>max</sub> [fmol/mg]
control	0.36 ± 0.05	2900 ± 290	0.40 ± 0.005	2200 ± 370	0.32 ± 0.01	1700 ± 350
+ NT	0.23 ± 0.07	2900 ± 600	0.70 ± 0.12	2300 ± 390	0.54 ± 0.03	1630 ± 230

<sup>a</sup>The K<sub>D</sub>-values of the three different systems were determined on membrane preparations of transiently transfected HEK293 cells of the coexpression D<sub>2L</sub>-NTS<sub>1</sub>, singly expressed D<sub>2L</sub> and the mixed single expressions of D<sub>2L</sub> and NTS<sub>1</sub> using [<sup>3</sup>H]spiperone for the saturation experiments. Experiments were performed in absence and presence of 10 μM NT. Data were derived from 4-15 individual experiments each done in triplicates.


**Table 2.** Modulation of  $K_D$  values of [ $^3H$ ]7-OH-DPAT at the  $D_{2L}$ -NTS $_1$ -heteromer in presence of different concentrations of NT and NT(8-13) and SR48692. Data were derived from 4 to 25 individual experiments each done in triplicates Significances were calculated in an unpaired *t*-test compared to control (\* and \*\*  $p < 0.001$  and  $p < 0.005$ , respectively).

	Co- expression of $D_{2L}$ and NTS $_1$		Co- expression of $D_{2L}$ and NTS $_1$	
	$K_D$ [nM]	$B_{max}$ [fmol/mg]	$K_D$ [nM]	$B_{max}$ [fmol/mg]
Control	$7.2 \pm 0.62$	$550 \pm 43$	7-OH-DPAT +100 nM NT(8-13)	$125 \pm 16$ * $380 \pm 90$
7-OH-DPAT + 100 nM NT	$62 \pm 11$ *	$420 \pm 100$	7-OH-DPAT +10 nM NT(8-13)	$47 \pm 14$ ** $410 \pm 65$
7-OH-DPAT +10 nM NT	$21 \pm 4.2$ *	$410 \pm 65$	7-OH-DPAT +1 nM NT(8-13)	$23 \pm 2.1$ * $500 \pm 54$
7-OH-DPAT + 400 nM SR48692	$6.9 \pm 0.51$	$600 \pm 78$	7-OH-DPAT + 400 nM SR48692 and 100 nM NT	$8.9 \pm 0.61$ $480 \pm 75$

**Figure 3.** Binding curve of homologous competition experiments using [<sup>3</sup>H]7-OH-DPAT in presence of 10 μM neurotensin. Curves with error bars representing the SEM derived from 6 individual experiments performed in triplicate.



**Figure 4.** Binding curve of homologous competition experiments using [<sup>3</sup>H]7-OH-DPAT in presence of 10 nM neurotensin. Curves with error bars representing the SEM derived from 5 individual experiments performed in triplicate.






**Table 3.** [<sup>3</sup>H]Neurotensin binding remained unchanged in presence of dopamine D<sub>2</sub> receptor agonist and antagonists. Influence of dopaminergics on [<sup>3</sup>H]neurotensin binding at the D<sub>2L</sub>-NTS<sub>1</sub>-heteromer compared with singly expressed NTS<sub>1</sub> receptor membranes and the mixture of mono-expressed D<sub>2L</sub> and NTS<sub>1</sub>.<sup>a</sup>

	Co- expression of D <sub>2L</sub> and NTS <sub>1</sub>		NTS <sub>1</sub>		Mixture of singly expressed NTS <sub>1</sub> and D <sub>2L</sub>	
	K <sub>D</sub> [nM]	B <sub>max</sub> [fmol/mg]	K <sub>D</sub> [nM]	B <sub>max</sub> [fmol/mg]	K <sub>D</sub> [nM]	B <sub>max</sub> [fmol/mg]
Control	1.6 ± 0.19	3700 ± 690	1.6 ± 0.16	4800 ± 490	1.3 ± 0.64	2400 ± 350
+ 7-OH-DPAT	2.6 ± 0.18	5900 ± 330		n.d.		n.d.
+ spiperone	1.1 ± 0.14	3800 ± 460		n.d.		n.d.

<sup>a</sup>The K<sub>D</sub>-values were determined on membrane preparations of transiently transfected HEK293 cells of the coexpressed D<sub>2L</sub>-NTS<sub>1</sub>, singly expressed NTS<sub>1</sub> and the mixed single expressions of D<sub>2L</sub> and NTS<sub>1</sub> using [<sup>3</sup>H]neurotensin for the saturation experiments. Experiments were performed in absence and presence of 1 μM spiperone and 140 nM 7-OH-DPAT, respectively. Data were derived from 3-12 individual experiments each done in triplicates. n.d. not determined

**Figure 5.** To control the membrane localization of transiently transfected HEK293 cells co-expressing the eYFP-tagged D<sub>2L</sub> receptor (yellow) and eCFP-labelled NTS<sub>1</sub> mutant receptors, confocal microscopy with CFP and YFP emission and excitation wavelengths were performed. The D<sub>2L</sub>-YFP construct (yellow, left) was shown to be co-localized in the plasma membrane with (A) NTS<sub>1</sub>W129A-eCFP (right, cyan) and (B) NTS<sub>1</sub>W134A-eCFP.




**Table 4.** Receptor binding data for the test compound FAUC326 at the porcine dopamine D<sub>1</sub>, serotonin 5-HT<sub>1A</sub>, 5-HT<sub>2</sub> and adrenergic α<sub>1</sub> as well as the human D<sub>2L</sub>, D<sub>2S</sub>, D<sub>3</sub> and D<sub>4</sub> receptors. Mean K<sub>i</sub> values with SEM are derived from 2 to 7 experiments each done in triplicates.

		K <sub>i</sub> -values (nM) ± SEM							
		[ <sup>3</sup> H] SCH23390		[ <sup>3</sup> H]spiperone			[ <sup>3</sup> H] WAY 100635	[ <sup>3</sup> H] ketanserin	[ <sup>3</sup> H] prazosin
		pD <sub>1</sub>	hD <sub>2L</sub>	hD <sub>2S</sub>	hD <sub>3</sub>	hD <sub>4,4</sub>	p5-HT <sub>1A</sub>	P5-HT <sub>2</sub>	pα <sub>1</sub>
	K <sub>0,5</sub>	6400 ±					6,5 ±		
		180					0,94	53 ± 4,9	100 ± 26
FAUC 326	K <sub>i high</sub>		0,64 ±	0,33 ±	0,90 ±				
			0,11	0,05	0,20	2,8 ± 0,70			
	K <sub>i low</sub>		30 ± 2,3	14 ± 2,0	16 ± 2,7	64 ± 15			

**Figure 6.** Neurotensin positively modulates the signaling of D2L in the coexpression with NTS1.

A) Stimulation of transiently transfected HEK cell coexpressing D2L and NTS1 receptors with 7-OH-DPAT (A) and FAUC326 (B) at discrete concentrations of neurotensin (NT). The data of representative experiment performed in triplicate are shown. The normalized and pooled data of 4-6 experiments performed in triplicates are shown for 7-OH-DPAT (C) and FAUC326 (D), were the basal value defined 0% and the increase over the basal for dopaminergic in the absence of NT 100%.



**Inhibition of cAMP accumulation assay.** Bioluminescence based cAMP-Glo™ assay (Promega) was performed according to the manufacturers instructions. Briefly, CHO cells expressing D<sub>2L</sub> wild receptor were seeded into a white 96-well plate (10 000 cells/well) 24 hr prior to the assay. Cells were first briefly washed with Krebs-Ringer Buffer (pH 7.4) to remove traces of serum and were incubated with various concentrations of substances in the presence of 20 μM forskolin in Krebs Ringer Buffer that contained 500 μM IBMX and 100 μM Ro 20-1724, pH 7.4. After 15 min of incubation at room temperature, the cells were lysed with cAMP-Glo lysis buffer. After lysis, the kinase reaction was performed with a reaction buffer containing PKA. At the end of the kinase reaction an equal volume of Kinase-Glo reagent was added. The plates were read with a luminescence protocol on a microplate reader Victor<sup>3</sup>V (Perkin-Elmer). The experiments were performed two to nine times per compound with each concentration in duplicate.

**PhosphoERK1/2 ELISA assay.** The PathScan phospho-p42/44 MAPK (Thr202/Tyr204) Sandwich ELISA (Cell Signaling) was performed according to manufactures instructions. Briefly,  $6 \times 10^6$  CHO cells that expressed D<sub>2L</sub> receptor were seeded in a 100 mm plate. The next day, cells were washed once with the serum free media and incubated in the presence of serum free media for additional 24 hr. On the day of the experiment, the medium was removed and replaced with the serum-free media containing various concentrations of the test substances as indicated and incubated for 5 min at 37°C. The wash with ice-cold PBS and the addition of the lysis buffer stopped the reaction. The plates were kept on ice, cells scraped, briefly sonicated (UP50H, Hielscher Ultrasound Technologies) and centrifuged at 15 000 g for 10 min. The supernatant was promptly diluted with the sample diluent and incubated overnight at 4°C in the well. After intensive washing steps, the detection of the phosphorylated ERK1/2 followed. The absorbance was read at 450 nm within 2 min after addition of STOP solution on Victor<sup>3</sup>V (Perkin Elmer) microplate reader. The experiment was performed four times per compound.


**Luciferase Reporter Gene Assay.** The luciferase reporter gene assay was performed according to the manufacturer's instructions (PathDetect Elk1 Trans-Reporting System, Stratagene, USA). A day before the transfection, HEK 293 cells were seeded in the 10 cm tissue culture dish. The cells were transfected with the TransIT-293 transfection reagent (Mirus Bio Corporation, Madison, WI) and 2.5 µg D<sub>2</sub>L, 2.5 µg NTS1, 5 µg reporter pFR-Luc, and 0.5 µg pFA2-Elk1 fusion *trans*-activator plasmid. Twenty-four hours after transfection, cells were trypsinized and washed once to remove FBS. Cells were resuspended in DMEM-F12 supplemented with 1% FBS, 2 mM L-glutamine, and 1% Pen-Strep and seeded into white half area 96-well plates (40000 cells/well). The test compounds were added at the indicated concentrations at a final volume of 50 µL and incubated for 24 h at 37°C and 5% CO<sub>2</sub>. To quantify an increase in luciferase expression, 50 µL of Bright-Glo reagent (Promega, Mannheim, Germany) was added to each well. After 3 min of incubation at RT and constant agitation to achieve complete cell lysis, luminescence was measured with a multiplate reader (Viktor<sup>3</sup>V, Perkin-Elmer, Rodgau Germany).

The data obtained from the luciferase reporter gene assay were normalized (using the treatment of coexpressed receptors with 7-OH-DPAT and FAUC326 and in the absence of NT as reference to set 0% and 100%), pooled and 95% confidence interval for EC<sub>50</sub> values and efficacy estimated.

**N-[(N'-Indan-2-yl-N'-propyl)-4-aminobutyl]pyrazolo[1,5-a]pyridine-3-carboxamide (FAUC 326)**

**<sup>1</sup>H NMR:**

<sup>1</sup>H (360 MHz CDCl<sub>3</sub>)





**$^{13}\text{C}$  NMR:**

$^{13}\text{C}$  (150 MHz  $\text{CDCl}_3$ )

